Edwards Lifesciences combines a durable franchise with structural pricing power, sustaining gross margins between 77.6% and 80.6% across the ten reported quarters while revenue grew 10.5% year over year to roughly $1.7B in the latest quarter.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue reached roughly $1.7B with 10.5% year-over-year growth and a 78.5% gross margin, but operating margin fell to 17.4% from 31.2% in 2026Q1, suggesting opex growth is outpacing gross profit.
Edwards Lifesciences benefits from strong institutional support, which bolsters investor confidence and stability.
Expected product approvals present significant growth potential, driving future revenue and market expansion.
The company's leadership in structural heart therapies positions it for sustained growth in the medtech sector.
Trailing total returns as of 11/7/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | $0.80+7.5% vs $0.74 | $1.7B+2.1% vs $1.7B |
Q3 2026 Jul 23, 2026 | $0.78+5.0% vs $0.74 | $1.7B+2.4% vs $1.7B |
Q2 2026 Apr 23, 2026 | $0.78+7.0% vs $0.73 | $1.6B+3.2% vs $1.6B |
Q1 2026 Feb 10, 2026 | $0.58-6.1% vs $0.62 | $1.6B+1.5% vs $1.5B |
Edwards Lifesciences NYSE: EW raised its 2026 sales and earnings guidance after third-quarter results exceeded management's expectations, with growth across its heart-valve businesses and regions.
EW tops Q3 earnings and revenue estimates as strong structural heart therapy sales drive margin expansion and prompt higher 2026 guidance.
Edwards Lifesciences Corporation (EW) Q3 2026 Earnings Call Transcript
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2026. Q3 Financial Highlights Q3 sales grew 10.5% to $1.72 billion1, constant currency2 sales grew 11.2% Q3 TAVR sales grew 8.0% to $1.24 billion1, constant currency2 sales grew 8.8% Q3 TMTT sales grew 44.0% to $207 million1,3, constant currency2 sales grew 45.6%3 Q3 EPS of $0.531; adjusted2 EPS of $0.801 which grew 19% versus prior year 2026 Outlook Increasing t.
Benchmark EW against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Edwards Lifesciences Corporation (EW)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $102.14 | $58.81B | 57.77 | 11.55% | 15.3% | 9.65% | — | |
| $101.80 | $130.7B | 25.01 | 8.43% | 13.93% | 10.51% | 2.78% | |
| $109.93 | $191.48B | 40.64 | 5.67% | 9.75% | 9% | 2.14% | |
| $42.75 | $63.54B | 17.79 | 19.87% | 16.56% | 13.74% | — | |
| $325.87 | $124.93B | 34.60 | 11.16% | 13.78% | 15.61% | 1.03% | |
| $105.59 | $20.43B | 26.33 | 7.2% | 8.96% | 6.05% | 0.91% |
Edwards Lifesciences Corporation (EW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Edwards Lifesciences Corporation (EW) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 4, 2026·SEC
Jul 23, 2026·SEC
May 8, 2026·SEC
Get notified when EW posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Edwards Lifesciences Corporation (EW) stock FAQ — growth, dividends, profitability & financials explained
Edwards Lifesciences Corporation (EW) reported $6.67B in revenue over the trailing twelve months. Revenue was $6.07B in fiscal year 2025. That is 570% more than the $905.0M of fiscal year 1999.
Edwards Lifesciences Corporation (EW) grew revenue by 13.4% over the trailing twelve months, compared with the twelve months before.
Yes. Edwards Lifesciences Corporation (EW) earned $1.02B in net income over the trailing twelve months (a 15.3% net margin).
Edwards Lifesciences Corporation (EW) had a return on equity (ROE) of 9.6% over the trailing twelve months. That is below the market's typical 10-15%.
Edwards Lifesciences Corporation (EW) generated $1.42B in free cash flow over the trailing twelve months.
